» Articles » PMID: 22533337

Marked Genetic Heterogeneity in Familial Myelodysplasia/acute Myeloid Leukaemia

Overview
Journal Br J Haematol
Specialty Hematology
Date 2012 Apr 27
PMID 22533337
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

The myelodysplastic syndromes (MDS) are heterogeneous and can evolve into acute myeloid leukaemia (AML). Rare familial cases are reported in which five disease genes have been identified to date (RUNX1, CEBPA, TERC, TERT and GATA2). Here we report the genetic categorization of 27 families with familial MDS/AML. All of these families were screened for RUNX1, CEBPA, TERC, TERT and GATA2 as well as TET2 and NPM1. Five of the 27 families had telomerase mutations; one had a RUNX1 mutation, while none were found to have TET2, CEBPA or NPM1 mutations. We identified four families with heterozygous GATA2 mutations, each associated with a different phenotype. While one of these mutations is novel, three have been previously reported: one has been described in dendritic cell, monocyte, B and NK lymphoid (DCML) deficiency and one is in a family that has been reported in a series with primary lymphoedema with a predisposition to AML (Emberger syndrome). In summary, genetic characterization was shown in 10 (four GATA2, three TERT, two TERC, one RUNX1) of these families; however 17 remain uncharacterized, highlighting marked genetic heterogeneity in familial MDS/AML and the scope for further functional pathways that could give rise to this group of disorders.

Citing Articles

Viewpoint: Pre- and post-lung transplant considerations for patients with ultra-short telomere length.

Shah P, Armanios M Eur Respir J. 2025; 65(3).

PMID: 39884762 PMC: 11883148. DOI: 10.1183/13993003.01545-2024.


Clonal evolution in inherited marrow failure syndromes predicts disease progression.

Schratz K Hematology Am Soc Hematol Educ Program. 2023; 2023(1):125-134.

PMID: 38066914 PMC: 10727088. DOI: 10.1182/hematology.2023000469.


Adult-onset hereditary myeloid malignancy and allogeneic stem cell transplantation.

Toya T, Harada H, Harada Y, Doki N Front Oncol. 2022; 12:997530.

PMID: 36185231 PMC: 9524153. DOI: 10.3389/fonc.2022.997530.


GATA2 deficiency and MDS/AML: Experimental strategies for disease modelling and future therapeutic prospects.

Kotmayer L, Romero-Moya D, Marin-Bejar O, Kozyra E, Catala A, Bigas A Br J Haematol. 2022; 199(4):482-495.

PMID: 35753998 PMC: 9796058. DOI: 10.1111/bjh.18330.


A structurally conserved human and telomerase catalytic core.

Wang Y, Gallagher-Jones M, Susac L, Song H, Feigon J Proc Natl Acad Sci U S A. 2020; 117(49):31078-31087.

PMID: 33229538 PMC: 7733840. DOI: 10.1073/pnas.2011684117.